Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Dooley

Showing results (141-150 of 263) with videos related to

Pageof 27
Sort By:
International Journal of Environmental Research and Public Health|February 15, 2022
Effects of Large-Scale Municipal Safe Routes to School Infrastructure on Student Active Travel and Physical Activity: Design, Methods, and Baseline Data of the Safe Travel Environment Evaluation in Texas Schools (STREETS) Natural ExperimentDeanna M Hoelscher, Leigh Ann Ganzar, Deborah Salvo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 14, 2003
Fluoroquinolone resistance in patients with newly diagnosed tuberculosisAmy Sarah Ginsburg, Nancy Hooper, Nikki Parrish, et al.
Clinical Pharmacology and Therapeutics|December 17, 2017
Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose ModificationsBenjamin Guiastrennec, Geetha Ramachandran, Mats O Karlsson, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 29, 2020
Subclinical tuberculosis and adverse infant outcomes in pregnant women with HIVH M Rickman, S Cohn, S G Lala, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2023
Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicinAllan Kengo, Kamunkhwala Gausi, Ruth Nabisere, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2023
Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicinAllan Kengo, Ruth Nabisere, Kamunkhwala Gausi, et al.
Journal of General Internal Medicine|January 10, 2023
Screen Time from Adolescence to Adulthood and Cardiometabolic Disease: a Prospective Cohort StudyJason M Nagata, Christopher M Lee, Feng Lin, et al.
Clinical Pharmacokinetics|June 6, 2022
Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with BedaquilineLénaïg Tanneau, Mats O Karlsson, Andreas H Diacon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 28, 2019
Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End TuberculosisJan-Willem C Alffenaar, Tawanda Gumbo, Kelly E Dooley, et al.
Journal of Multimorbidity and Comorbidity|April 8, 2024
Multimorbidity trajectories in early adulthood and middle age: Findings from the CARDIA prospective cohort studyC Barrett Bowling, Richard A Faldowski, Richard Sloane, et al.
Pageof 27

Showing results (141-150 of 263) with videos related to

Sort By:
Pageof 27
International Journal of Environmental Research and Public Health|February 15, 2022
Effects of Large-Scale Municipal Safe Routes to School Infrastructure on Student Active Travel and Physical Activity: Design, Methods, and Baseline Data of the Safe Travel Environment Evaluation in Texas Schools (STREETS) Natural ExperimentDeanna M Hoelscher, Leigh Ann Ganzar, Deborah Salvo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 14, 2003
Fluoroquinolone resistance in patients with newly diagnosed tuberculosisAmy Sarah Ginsburg, Nancy Hooper, Nikki Parrish, et al.
Clinical Pharmacology and Therapeutics|December 17, 2017
Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose ModificationsBenjamin Guiastrennec, Geetha Ramachandran, Mats O Karlsson, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 29, 2020
Subclinical tuberculosis and adverse infant outcomes in pregnant women with HIVH M Rickman, S Cohn, S G Lala, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2023
Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicinAllan Kengo, Kamunkhwala Gausi, Ruth Nabisere, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2023
Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicinAllan Kengo, Ruth Nabisere, Kamunkhwala Gausi, et al.
Journal of General Internal Medicine|January 10, 2023
Screen Time from Adolescence to Adulthood and Cardiometabolic Disease: a Prospective Cohort StudyJason M Nagata, Christopher M Lee, Feng Lin, et al.
Clinical Pharmacokinetics|June 6, 2022
Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with BedaquilineLénaïg Tanneau, Mats O Karlsson, Andreas H Diacon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 28, 2019
Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End TuberculosisJan-Willem C Alffenaar, Tawanda Gumbo, Kelly E Dooley, et al.
Journal of Multimorbidity and Comorbidity|April 8, 2024
Multimorbidity trajectories in early adulthood and middle age: Findings from the CARDIA prospective cohort studyC Barrett Bowling, Richard A Faldowski, Richard Sloane, et al.
Pageof 27